Fatal infusion reactions to cetuximab: Role of immunoglobulin E-mediated anaphylaxis

Journal of Clinical Oncology

Volumn 30, Issue 3, 2012, Pages 334-

  Pointreau, Yoann ^a   Commins, Scott P ^b   Calais, Gilles ^a   Watier, Hervé ^a   Platts Mills, Thomas A E ^b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; GALACTOSYLGALACTOSE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M;

ANAPHYLAXIS; COLON CANCER; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; HEAD AND NECK CANCER; HUMAN; LETTER; METASTASIS; PRIORITY JOURNAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; MALE;

EID: 84855983253     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.4701     Document Type: Letter

References (8)

1. Tronconi MC, Sclafani F, Rimassa L, et al: Fatal infusion reaction to cetuximab: The need for predictive risk factors and safer patient selection. J Clin Oncol 29:e680-e681, 2011
2. Chung CH, Mirakhur B, Chan E, et al: Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109-1117, 2008 (Pubitemid 351398485)
3. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, et al: Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 64:210-225, 2007 (Pubitemid 350030959)
4. O'Neil BH, Allen R, Spigel DR, et al: High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina: Association with atopic history. J Clin Oncol 25:3644-3648, 2007 (Pubitemid 47372602)
5. George TJ Jr, Laplant KD, Walden EO, et al: Managing cetuximab hypersensitivity-infusion reactions: Incidence, risk factors, prevention, and retreatment. J Support Oncol 8:72-77, 2010
6. Commins SP, James HR, Kelly LA, et al: The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol 127:1286-1293, 2011
7. Mariotte D, Dupont B, Gervais R, et al: Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 3:396-401, 2011
8. Daguet A, Watier H: 2nd Charles Richet et Jules Héricourt Workshop: Therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs 3:417-421, 2011